Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients
Karen F Urbancic, Daisy Pisasale, Joel Wight, Jason A Trubiano
TRANSPLANT INFECTIOUS DISEASE | WILEY | Published : 2018
Dapsone may be used for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in hematology patients receiving immunosuppressive therapy or after hematopoietic stem cell transplant (HSCT) in the setting of trimethoprim-sulfamethoxazole (TMP-SMX) adverse drug reaction (ADR) history. Dapsone-induced hematological toxicities such as oxidative hemolysis may limit use in these patients and modern assessments of dapsone allergy cross-reactivity in non-HIV patients with a sulfonamide allergy are largely absent. The aim of this single-centre, retrospective study was to describe dapsone usage in hematology patients requiring PJP prophylaxis, including HSCT recipients, over a 12-month period in terms of ..View full abstract
Related Projects (2)
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by NHMRC Early Careers Fellowship
K.F.U is supported by a National Health and Medical Research Council (NHMRC) postgraduate research scholarship (APP1133479) and J.A.T by a NHMRC Early Careers Fellowship (APP1139902).